Heart disease. Other functional disturbances following cardiac surgery
Conditions
Interventions
Intervention 1: at this clinical trial study, the control group consists of 40 patients recieve Plavix tablets as an antiplatetlet agent. The prescribed dose is 75 mg of Clopidogrel per day for each
Treatment - Drugs
at this clinical trial study, the control group consists of 40 patients recieve Plavix tablets as an antiplatetlet agent. The prescribed dose is 75 mg of Clopidogrel per day for each group. It shoul
at this clinical trial study, the intervantion group consists of 40 patients recieve Osvix tablets as an antiplatetlet agent. The prescribed dose is 75 mg of Clopidogrel per day for each group. It s
Sponsors
Research Deputy of Hamadan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients undergoing open heart surgery Exclusion criteria: 1- Patients with a prior events of acute coronary syndrome, 2- Hepatic insufficiency, 3- History of significant bleeding disorder,4- Those already taking anti-platelet and/or anticoagulant therapy, 5- Age less than 20 and over than 75.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet-rich plasma. Timepoint: 30 days after heart surgery. Method of measurement: Aggregometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adenosine diphosphate. Timepoint: 30 days after heart surgery. Method of measurement: Aggrigometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehzad Imani
Hamadan University of Medical Sciences
Outcome results
None listed